Cargando…

Bispecific antibodies—effects of point mutations on C(H)3-C(H)3 interface stability

A new format of therapeutic proteins is bispecific antibodies, in which two different heavy chains heterodimerize to obtain two different binding sites. Therefore, it is crucial to understand and optimize the third constant domain (C(H)3-C(H)3) interface to favor heterodimerization over homodimeriza...

Descripción completa

Detalles Bibliográficos
Autores principales: Pomarici, Nancy D, Fernández-Quintero, Monica L, Quoika, Patrick K, Waibl, Franz, Bujotzek, Alexander, Georges, Guy, Liedl, Klaus R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741699/
https://www.ncbi.nlm.nih.gov/pubmed/36468666
http://dx.doi.org/10.1093/protein/gzac012
Descripción
Sumario:A new format of therapeutic proteins is bispecific antibodies, in which two different heavy chains heterodimerize to obtain two different binding sites. Therefore, it is crucial to understand and optimize the third constant domain (C(H)3-C(H)3) interface to favor heterodimerization over homodimerization, and to preserve the physicochemical properties, as thermal stability. Here, we use molecular dynamics simulations to investigate the dissociation process of 19 C(H)3-C(H)3 crystal structures that differ from each other in few point mutations. We describe the dissociation of the dimeric interface as a two-steps mechanism. As confirmed by a Markov state model, apart from the bound and the dissociated state, we observe an additional intermediate state, which corresponds to an encounter complex. The analysis of the interdomain contacts reveals key residues that stabilize the interface. We expect that our results will improve the understanding of the C(H)3-C(H)3 interface interactions and thus advance the developability and design of new antibodies formats.